We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Cardiovascular Systems Unveils Favorable LIBERTY 360 Data
Read MoreHide Full Article
Medical device manufacturer Cardiovascular Systems, Inc. recently released one-year data from its LIBERTY 360° clinical study in a late-breaking presentation at the 2017 Amputation Prevention Symposium (AMP) in Chicago. LIBERTY 360° is a prospective, observational, multi-center post-market study. The study was based on more than 1,200 patients at 51 sites across the U.S., including 501 patients with claudication, 603 patients with critical limb ischemia (CLI) and 100 patients with the most severe form of CLI.
The study examined the acute and long-term clinical and economic outcomes of peripheral vascular interventions (PVI) in peripheral artery disease (PAD) patients. LIBERTY 360° included all FDA-approved endovascular devices to treat PAD.
The 12-month data from this study demonstrated that peripheral endovascular intervention marked improvement across all Ruthetford Classes along with high freedom from major adverse events. To be precise, LIBERTY 360°showed that PVI can help prevent amputation for patients with PAD, specifically CLI.
As per the company’s press release, around 18 million Americans suffer from PAD, which is caused by the accumulation of plaque in peripheral arteries reducing blood flow. We believe that the company is adopting appropriate strategic moves to capture the niche market.
In this regard to note, the company recently received FDA approval for radial access Diamondback 360 Peripheral Orbital Atherectomy Device to treat PAD. The commercial availability is expected in the beginning of calendar year 2018.
Some notable stocks in the broader industry are Haemonetics Corporation (HAE - Free Report) , Stryker Corporation (SYK - Free Report) and Lantheus Holdings, Inc. .
Zacks' 10-Minute Stock-Picking Secret
Since 1988, the Zacks system has more than doubled the S&P 500 with an average gain of +25% per year. With compounding, rebalancing, and exclusive of fees, it can turn thousands into millions of dollars.
But here's something even more remarkable: You can master this proven system without going to a single class or seminar. And then you can apply it to your portfolio in as little as 10 minutes a month.
Image: Bigstock
Cardiovascular Systems Unveils Favorable LIBERTY 360 Data
Medical device manufacturer Cardiovascular Systems, Inc. recently released one-year data from its LIBERTY 360° clinical study in a late-breaking presentation at the 2017 Amputation Prevention Symposium (AMP) in Chicago. LIBERTY 360° is a prospective, observational, multi-center post-market study. The study was based on more than 1,200 patients at 51 sites across the U.S., including 501 patients with claudication, 603 patients with critical limb ischemia (CLI) and 100 patients with the most severe form of CLI.
The study examined the acute and long-term clinical and economic outcomes of peripheral vascular interventions (PVI) in peripheral artery disease (PAD) patients. LIBERTY 360° included all FDA-approved endovascular devices to treat PAD.
The 12-month data from this study demonstrated that peripheral endovascular intervention marked improvement across all Ruthetford Classes along with high freedom from major adverse events. To be precise, LIBERTY 360°showed that PVI can help prevent amputation for patients with PAD, specifically CLI.
As per the company’s press release, around 18 million Americans suffer from PAD, which is caused by the accumulation of plaque in peripheral arteries reducing blood flow. We believe that the company is adopting appropriate strategic moves to capture the niche market.
In this regard to note, the company recently received FDA approval for radial access Diamondback 360 Peripheral Orbital Atherectomy Device to treat PAD. The commercial availability is expected in the beginning of calendar year 2018.
Some notable stocks in the broader industry are Haemonetics Corporation (HAE - Free Report) , Stryker Corporation (SYK - Free Report) and Lantheus Holdings, Inc. .
Zacks' 10-Minute Stock-Picking Secret
Since 1988, the Zacks system has more than doubled the S&P 500 with an average gain of +25% per year. With compounding, rebalancing, and exclusive of fees, it can turn thousands into millions of dollars.
But here's something even more remarkable: You can master this proven system without going to a single class or seminar. And then you can apply it to your portfolio in as little as 10 minutes a month.
Learn the secret >>